Belite Bio Inc Adr (BLTE)

08:05 AM

Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK

08:05 AM

07:42 AM

Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo

07:42 AM

May 22, 2026

Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - MSN

May 22, 2026

May 22, 2026

Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily

May 22, 2026

May 22, 2026

Benchmark reiterates Belite Bio stock rating on drug development progress - Investing.com

May 22, 2026

May 22, 2026

Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail

May 22, 2026

May 22, 2026

Benchmark reiterates Belite Bio stock rating on drug development progress By Investing.com - Investing.com Canada

May 22, 2026

May 22, 2026

BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill

May 22, 2026

May 21, 2026

Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target - TipRanks

May 21, 2026

May 21, 2026

H.C. Wainwright reiterates Belite Bio stock rating on NDA progress By Investing.com - Investing.com South Africa

May 21, 2026

May 21, 2026

Earnings Scheduled For May 20, 2026 - Sahm

May 21, 2026

May 21, 2026

H.C. Wainwright reiterates Belite Bio stock rating on NDA progress - Investing.com

May 21, 2026

May 21, 2026

Belite Bio Q1 2026 Earnings Call Transcript - MarketBeat

May 21, 2026

May 21, 2026

Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses By GuruFocus - Investing.com Canada

May 21, 2026

May 21, 2026

BLTE Stock Price, Quote & Chart | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill

May 21, 2026

May 20, 2026

Belite Bio Ramps Toward Tinlarebant Launch - TipRanks

May 20, 2026

May 20, 2026

Belite Bio Q1 Earnings Call Highlights - inkl

May 20, 2026

May 20, 2026

Belite Bio (BLTE) Q1 2026 Earnings Transcript - The Globe and Mail

May 20, 2026

May 20, 2026

Earnings call transcript: Belite Bio beats Q1 2026 EPS estimates, stock dips - Investing.com

May 20, 2026

May 20, 2026

Belite Bio Releases Q1 2026 Financial Results - AlphaStreet

May 20, 2026

May 20, 2026

Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base - TipRanks

May 20, 2026

May 20, 2026

Belite Bio Q1 Adjusted Loss Widens - marketscreener.com

May 20, 2026

May 20, 2026

Belite Bio stock gains 2% on first-quarter earnings beat By Investing.com - Investing.com India

May 20, 2026

May 20, 2026

Earnings Flash (BLTE) Belite Bio, Inc Posts Q1 Adjusted Loss $0.34 per Share, vs. FactSet Est of $-0.69 - marketscreener.com

May 20, 2026

May 20, 2026

Belite Bio stock gains 2% on first-quarter earnings beat - Investing.com

May 20, 2026

May 20, 2026

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - Caledonian Record

May 20, 2026

May 20, 2026

Belite Bio (NASDAQ: BLTE) starts tinlarebant NDA as Q1 2026 loss deepens - Stock Titan

May 20, 2026

May 20, 2026

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewswire Inc.

May 20, 2026

May 20, 2026

Belite Bio (BLTE) Is Down 6.6% After Swiss Orphan Status, FDA Filing Progress For Tinlarebant - Sahm

May 20, 2026

May 18, 2026

Belite Bio receives Swiss orphan drug status for tinlarebant By Investing.com - Investing.com Nigeria

May 18, 2026

May 18, 2026

Belite Bio receives Swiss orphan drug status for tinlarebant - Investing.com

May 18, 2026

May 18, 2026

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland - marketscreener.com

May 18, 2026

May 15, 2026

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - The Manila Times

May 15, 2026

May 14, 2026

Belite Bio (BLTE) CEO & Chairman reports 1.25M shares, including vested awards - Stock Titan

May 14, 2026

May 13, 2026

Transcript : Belite Bio, Inc Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03 - marketscreener.com

May 13, 2026

May 13, 2026

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results - marketscreener.com

May 13, 2026

May 11, 2026

Trading the Move, Not the Narrative: (BLTE) Edition - Stock Traders Daily

May 11, 2026

May 08, 2026

Belite Bio (BLTE) CSO exits 666 ADS in 10b5-1 stock sales - Stock Titan

May 08, 2026

May 07, 2026

Belite Bio (BLTE) CSO offloads 1,000 ADS in Rule 10b5-1 sales - Stock Titan

May 07, 2026

May 06, 2026

Belite Bio (BLTE) CSO sells 1,000 ADSs in Rule 10b5-1 trades - Stock Titan

May 06, 2026

May 05, 2026

Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares - Investing.com Nigeria

May 05, 2026

May 05, 2026

Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS - Stock Titan

May 05, 2026

May 04, 2026

Belite Bio CSO Nathan Mata sells $155,777 in shares By Investing.com - Investing.com Australia

May 04, 2026

May 04, 2026

Belite Bio CSO Nathan Mata sells $155,777 in shares - Investing.com

May 04, 2026

May 04, 2026

Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160 - Stock Titan

May 04, 2026

May 01, 2026

Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan

May 01, 2026

May 01, 2026

Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance

May 01, 2026

May 01, 2026

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

May 01, 2026

Apr 30, 2026

Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus - Barchart.com

Apr 30, 2026

Apr 30, 2026

Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat

Apr 30, 2026